Dermapharm Holding SE - subsidiary axicorp GmbH breaks ground for a new building near Frankfurt/Main Grünwald, September 30, 2020 - Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, is beginning with construction of a state-of-the-art production, storage and administ [ … ]

Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine Grünwald, September 10, 2020 - Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, will support the vaccine developer BioNTech SE in part of the vacc [ … ]

Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU) No. 596/2014 on Market Abuse, as amended (Market Abuse Regulation - MAR)   Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE Grünwald, September 10, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Ma [ … ]

Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic » Group revenue up 14% year-on-year to EUR 378 million » Adjusted EBITDA of EUR 92 million around 2% above previous year's level » Forecast for 2020 raised to 12-15% revenue and 8-10% EBITDA growthGrünwald, 9 September 2020 ‒ Dermapharm Holding [ … ]

Dermapharm remains on growth course despite corona pandemic in the first half of 2020 » Group revenue up 14% year-on-year to EUR 378 million » Adjusted EBITDA of EUR 92 million around 2% above previous year's level » Allergopharma consolidated for the first time » Forecast for 2020 raised to 12-15% revenue and 8-10% EBITDA growthGrünwald, 21 Augus [ … ]